david gandara, md, discusses pembrolizumab vs docetaxel for previously treated nsclc patients
Published 8 years ago • 53 plays • Length 0:31
Download video MP4
Download video MP3
Similar videos
-
1:01
david r. gandara, md, shares the benefits of using ramucirumab plus docetaxel in 2nd line nsclc
-
0:46
david gandara, md, discusses considerations when choosing between immunotherapy and chemotherapy
-
0:58
david gandara, md,, discusses pd-l1 expression and selecting the appropriate agent in nsclc patients
-
1:32
david gandara, md, talks about the potential impact of immunotherapy in 1st line nsclc
-
3:52
keynote 10: pembrolizumab vs docetaxel for nsclc
-
4:12
immunotherapy for cancer: pembrolizumab #cancer #immunotherapy #malignancy
-
25:49
medpix video - diffuse gliomas
-
8:38
#pembrolizumab | uses, dosage, side effects and mechanism | keytruda
-
0:59
david gandara, md, discusses the positioning of cyramza post platinum therapy in nsclc patients
-
0:25
david r. gandara, md, on continuing pemextrexed maintenance
-
3:54
pembrolizumab: new drug for advanced lung cancer
-
1:41
david r. gandara, md, discusses drug sequencing as a result of keynote 189 and 42 results
-
1:40
dr. gandara discusses the oak trial for lung cancer
-
3:47
pembrolizumab as treatment for oligometastatic nsclc
-
1:02
david gandara, md, current thinking regarding testing for pd-l1 biomarker in nsclc patients
-
1:20
dr. david gandara describes exciting new lung cancer research
-
2:03
dr. david gandara discusses multiplexing molecular tests for nsclc
-
0:44
david r. gandara, md, discusses exciting new developments in lung cancer here at asco 2018
-
2:13
dr. malhotra on pembrolizumab during concurrent chemoradiation in nsclc
-
1:55
dr. gandara on the impact of immunotherapy on the tumor microenvironment in lung cancer
-
1:50
pd-l1 agents in the treatment of nsclc
-
1:02
dr. gandara on the mystic trial for lung cancer
Clip.africa.com - Privacy-policy